- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02806284
Pneumococci and Hib Vaccination After Neurotrauma or Neurosurgery
Pneumococci and Hib Vaccination Early and Late After Neurotrauma or Neurosurgery
Study Overview
Detailed Description
There is a risk of meningitis after neurotrauma and different actions have been taken to reduce this risk. Prophylactic antibiotics are often administered, although at present there is little evidence to support such a regimen. Increasing problems with antibiotic resistance heightens the need for pertinent use of antibiotics.
Even if most of these infections occur early in the course, the risk appears to persist for many years and almost half of the posttraumatic meningitis cases occur after one month. Streptococcus pneumoniae is the most common causative agent and pneumococcal vaccination after neurotrauma is now recommended in several national guidelines. There are, however, no recommendations of when to administer the vaccine. In clinical practice, vaccination is most often performed several weeks after the trauma. Because the risk of meningitis is at the highest shortly after the trauma, vaccination within days would be preferable. Until recently, pneumococcal polysaccharide vaccine (PPSV) was the most common recommendation. During recent years pneumococcal conjugate vaccines (PCV) have been introduced, offering long-term protection and is now recommended in the USA.
Trauma, as well as surgery, activate the innate immune system resulting in, among other things, decreased T-cell function. Patients with injuries of the central nervous system (CNS) may show signs of a specific CNS-injury-induced immune deficiency syndrome (CIDS), which is also characterized by impaired T-cell activity. Accordingly, it can be speculated that ongoing anti-inflammatory response after trauma, here referred to as trauma-induced immune deficiency syndrome (TIDS), and CIDS by impaired T-cell function could negatively affect the response to vaccines, especially to T-cell dependent conjugate vaccines. In the present thesis, focus will be the impact of TIDS and CIDS on the response to T-cell dependent and T-cell independent vaccines.
Methods
Vaccination A conjugate vaccine against Haemophilus influenzae type b (Hib) was chosen as the T-cell-dependent antigen. All patients received a single subcutaneous injection of 0.5 ml Act-HIB® (Sanofi Pasteur MSD, Lyon, France) in the upper right arm. A 0.5 ml dose of this vaccine contains 10 μg of Hib polysaccharide conjugated to 24 micrograms of tetanus protein.
All patients also received, at the same time, a single subcutaneous injection of 0.5 ml Pneumovax® (Sanofi Pasteur MSD AB, Lyon, France) (PPSV23) containing 25 μg of purified capsular polysaccharide from each of the 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F) in the upper left arm.
Patients in the NT and NS groups were vaccinated within 10 days after trauma or surgery. Control patients were vaccinated, according to the local routine for pneumococcal vaccination, at least three weeks after trauma or surgery.
Adverse reactions to the vaccine were recorded in the case report form.
Sera collection and analysis Pre-vaccination sera were collected just before vaccination and post-vaccination sera were obtained three and six weeks after vaccination. Samples were stored at -70oC pending analysis. The laboratory was blinded with respect to group assignment of the patients.
IgG antibody concentrations to Hib polysaccharide were determined by enzyme immunoassay which is an established and accredited methodology.
An anti-Hib polysaccharide antibody concentration of 0.15 -1.0 μg/ml has been associated with long-term protection against invasive Hib infection after vaccination of children with Hib polysaccharide vaccine. Based on previous experience in children, a post-vaccination concentration of 10 μg/ml, 10 times the upper supposed protective concentration, was chosen as the target level for a good response to the vaccination in this study.
Serotype-specific anti-polysaccharide binding IgG antibody levels to serotypes 4, 6B, 9V, 14, 18C, 19F and 23F were determined by enzyme immunoassay which is an established and accredited methodology.
A serotype-specific IgG >0.35 μg/ml has been defined as the correlate of protection for invasive disease in infant recipients of (PCV). The true correlate of protection for adults after vaccination with PPSV23 is not known. The value of 1.0 μg/ml was chosen as the target level for a good response to the vaccination in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Basilar skull fracture or transsphenoidal pituitary gland surgery
- Own or presumed consent (by next of kin of unconscious)
Exclusion criteria
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Neurotrauma
Patients with basilar skull fracture with or without known cerebrospinal fluid leakage were enrolled in the neurotrauma (NT) group.
All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from trauma.
|
described in "Arm description"
Other Names:
|
ACTIVE_COMPARATOR: Neurosurgery
Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group.
All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
|
described in "Arm description"
Other Names:
|
ACTIVE_COMPARATOR: Control
All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier.
All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.
They were vaccinated at least three weeks after trauma or surgery.
The vaccines were administered by subcutaneous injections.
|
described in "Arm description"
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline of IgG anti-Hib (ug/ml)
Time Frame: baseline and 3 weeks
|
baseline and 3 weeks
|
Change from baseline of IgG anti-Hib (ug/ml)
Time Frame: baseline and 6 weeks
|
baseline and 6 weeks
|
Change from baseline of specific IgG against pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (ug/ml)
Time Frame: baseline and 3 weeks
|
baseline and 3 weeks
|
Change from baseline of specific IgG against pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (ug/ml)
Time Frame: baseline and 6 weeks
|
baseline and 6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jan Sjölin, Professor, Uppsala University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPN 00-254
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningitis
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
University Hospital, Strasbourg, FranceCompleted
-
University Medical Centre LjubljanaHarvard University; University of Ljubljana School of Medicine, Slovenia; Slovenian...Unknown
-
University of MinnesotaNational Institute of Neurological Disorders and Stroke (NINDS); Medical Research... and other collaboratorsCompletedCryptococcal Meningitis | Fungal MeningitisUganda
-
Rambam Health Care CampusWithdrawnGram Negative Meningitis | Post Traumatic Bacterial MeningitisIsrael
-
Assiut UniversityUnknown
-
Brigham and Women's HospitalActive, not recruitingPreventive Immunization; MeningitisUnited States
-
Charite University, Berlin, GermanyRecruitingBacterial Meningitis | Implant Infection | Fungal MeningitisGermany
-
Matinas BioPharma Nanotechnologies, Inc.University of MinnesotaNot yet recruitingCryptococcal Meningitis
Clinical Trials on PPSV23, Act-HIB
-
Viscogel ABKarolinska Institutet; Pharma Consulting Group ABCompleted
-
Beijing Minhai Biotechnology Co., LtdUnknownHaemophilus Influenzae Type b InfectionsChina
-
SanofiCompletedPertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type bChina
-
Novartis VaccinesCompletedMeningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type bChina
-
GlaxoSmithKlineCompletedNeisseria Meningitidis | Haemophilus Influenzae Type bUnited States
-
SanofiCompletedPertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type BChina
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Haemophilus Influenzae Type bChina
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy SubjectsNetherlands
-
Idorsia Pharmaceuticals Ltd.Completed
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type bChina